Compare Expedia Group Inc (EXPE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Organon & Co. Common Stock — how do they compare? Expedia Group Inc trades at $275 (market cap $32.82B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Expedia Group Inc is far larger — about 9.1× Organon & Co. Common Stock's market cap, and Expedia Group Inc pays the higher dividend (0.7%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Organon & Co. Common Stock for 0 Days on average.
| EXPE | OGN | |
|---|---|---|
Market Cap | $32.82B | $3.62B |
Volume | 1,337,882 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $13.81 |
52-Week Low | $188.51 | $5.70 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.38B | $11.04B |
Dividend Yield | 0.7% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.69, up 2.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 17.2, net income margin of 12.97%, and positive cash flow trends. Recent news highlights competitive threats from AI agents but also underscores Expedia's growth in B2B bookings and strategic partnerships.
The outlook for EXPE is positive, supported by earnings momentum and a consensus price target of $335.06, though risks include AI disruption and competitive pressures. Revenue growth and margin expansion present opportunities, but investor caution is warranted given mixed analyst ratings and market volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
